Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin

A Hugh Mostafid; Joan Palou Redorta; Richard Sylvester; J Alfred Witjes

doi:10.1016/j.eururo.2014.11.031

Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guérin

Eur Urol. 2015 Mar;67(3):359-60. doi: 10.1016/j.eururo.2014.11.031. Epub 2014 Nov 28.

Authors

A Hugh Mostafid¹, Joan Palou Redorta², Richard Sylvester³, J Alfred Witjes⁴

Affiliations

¹ Department of Urology, Royal Surrey County Hospital, Guildford, UK. Electronic address: Hugh.Mostafid@nhs.net.
² Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.
³ Headquarters, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁴ Department of Urology, Radboud UMC, Nijmegen, The Netherlands.

PMID: 25442053
DOI: 10.1016/j.eururo.2014.11.031

Abstract

Optimal management of high-risk non-muscle-invasive bladder cancer during the current bacillus Calmette-Guérin (BCG) shortage is challenging. Although no evidence-based guidelines exist for this specific situation, current management options can be adapted for when BCG supplies are limited or when BCG is unavailable.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / supply & distribution*
BCG Vaccine / supply & distribution*
Delivery of Health Care*
Humans
Neoplasm Invasiveness
Patient Safety
Practice Guidelines as Topic
Risk Assessment
Risk Factors
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / pathology

Substances

Antineoplastic Agents
BCG Vaccine